Phase 1 study of trimethylpurin-6-ylammonium chloride (NSC-51095).
D000328:Adult; D000368:Aged; D000643:Ammonium Chloride / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008697:Methane / Q000627:therapeutic use*; D008875:Middle Aged; D011687:Purines / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D011687:Purines; D000643:Ammonium Chloride; D008697:Methane